| Year |
Citation |
Score |
| 2019 |
Kleinschmidt-DeMasters B, Rosenblum M, Kerr J, Lillehei K. RARE-02. SYMPTOMATIC SALIVARY GLAND-LIKE TUMORS OF THE SELLAR REGION: ADDITIONAL FEATURES AND REVIEW OF THE LITERATURE Neuro-Oncology. 21: vi221-vi221. DOI: 10.1093/Neuonc/Noz175.925 |
0.307 |
|
| 2017 |
Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, Olson JJ, Ormond DR. Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. Journal of Neuro-Oncology. PMID 29081037 DOI: 10.1007/S11060-017-2656-9 |
0.319 |
|
| 2016 |
Lillehei K, Davies K, Aisner D, Kleinschmidt-DeMasters B. RARE-43. SEARCH FOR DRUGGABLE TARGETS IN PRIMARY NERVOUS SYSTEM MELANOTIC TUMORS: MELANOCYTOMAS, MELANOTIC SCHWANNOMAS, PRIMARY MELANOMAS Neuro-Oncology. 18: vi169-vi169. DOI: 10.1093/Neuonc/Now212.705 |
0.309 |
|
| 2016 |
Ryken T, Scullin E, Smith K, Lillehei K. Actr-48. A Multicenter, 500-Patient, Prospective Observational Registry Of The Performance Of Carmustine Wafers For Cns Malignancies Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now212.046 |
0.322 |
|
| 2015 |
Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, Lillehei K, Chen C. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. Journal of Neuro-Oncology. 123: 251-7. PMID 25920710 DOI: 10.1007/S11060-015-1791-4 |
0.367 |
|
| 2014 |
Ney D, Kleinschmidt-DeMasters BK, Carlson J, Damek D, Gaspar L, Kavanagh B, Waziri A, Lillehei K, Reddy K, Chen C. RT-24 * EXTENT OF CEREBRAL RADIONECROSIS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED ON A CLINICAL TRIAL WITH HYPOFRACTIONATED INTENSITY-MODULATED RADIATION THERAPY (HYPO-IMRT) COMBINED WITH TEMOZOLOMIDE (TMZ) AND BEVACIZUMAB (BEV) Neuro-Oncology. 16: v192-v192. DOI: 10.1093/Neuonc/Nou270.21 |
0.407 |
|
| 2012 |
Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 84: 655-60. PMID 22483738 DOI: 10.1016/J.Ijrobp.2012.01.035 |
0.372 |
|
| 2012 |
Fields EC, Damek D, Gaspar LE, Liu AK, Kavanagh BD, Waziri A, Lillehei K, Chen C. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 82: 51-7. PMID 21035955 DOI: 10.1016/J.Ijrobp.2010.09.008 |
0.377 |
|
| 2012 |
Reddy K, Damek D, Gaspar LE, Ney D, Kavanagh BD, Waziri A, Lillehei K, Stuhr K, Chen C. Hypofractionated Intensity Modulated Radiation Therapy Altered Patterns of Failure in Patients With Glioblastoma Multiforme Treated on a Phase II Trial International Journal of Radiation Oncology Biology Physics. 84. DOI: 10.1016/J.Ijrobp.2012.07.699 |
0.316 |
|
| 2011 |
Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics. 81: 1066-74. PMID 20932651 DOI: 10.1016/J.Ijrobp.2010.07.021 |
0.401 |
|
| 2011 |
Rusthoven KE, Olsen C, Franklin W, Kleinschmidt-DeMasters BK, Kavanagh BD, Gaspar LE, Lillehei K, Waziri A, Damek DM, Chen C. Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series. International Journal of Radiation Oncology, Biology, Physics. 81: 211-7. PMID 20732762 DOI: 10.1016/J.Ijrobp.2010.04.069 |
0.416 |
|
| 2011 |
Reddy K, Damek D, Gaspar L, Ney D, Kavanagh B, Waziri A, Lillehei K, Stuhr K, Chen C. Phase II Trial of Hypofractionated Intensity Modulated Radiotherapy to 60 Gy in 10 Fractions with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma Multiforme International Journal of Radiation Oncology Biology Physics. 81. DOI: 10.1016/J.Ijrobp.2011.06.268 |
0.34 |
|
| 2009 |
Chen C, Damek D, Waziri A, Gaspar LE, Lillehei K, Kane M, Robischon M, Kavanagh B. A Phase I Dose per Fraction Escalation Study of Hypofractionated Intensity-modulated Radiation Therapy with Temozolomide Chemotherapy for Patients with Newly Diagnosed Glioblastoma International Journal of Radiation Oncology Biology Physics. 75. DOI: 10.1016/J.Ijrobp.2009.07.251 |
0.342 |
|
| 2008 |
Schwer AL, Damek DM, Kavanagh BD, Gaspar LE, Lillehei K, Stuhr K, Chen C. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. International Journal of Radiation Oncology, Biology, Physics. 70: 993-1001. PMID 17967517 DOI: 10.1016/J.Ijrobp.2007.07.2382 |
0.379 |
|
| 2006 |
Chen C, Damek D, Gaspar LE, Lillehei K, Raben D, Ojemann S, Kavanagh B. 1121 : A Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy in Combination With ZD1839 (IRESSA®) in Patients With Recurrent Malignant Gliomas International Journal of Radiation Oncology Biology Physics. 66. DOI: 10.1016/J.Ijrobp.2006.07.386 |
0.379 |
|
| 1991 |
Samuels MH, Henry P, Kleinschmidt-Demasters BK, Lillehei K, Ridgway EC. Pulsatile glycoprotein hormone secretion in glycoprotein-producing pituitary tumors. The Journal of Clinical Endocrinology and Metabolism. 73: 1281-8. PMID 1955510 DOI: 10.1210/Jcem-73-6-1281 |
0.349 |
|
| Show low-probability matches. |